Authors/Disclosures
|
Rup Tandan, MD, FRCP, FAAN
(University of Vermont (UVM)/UVM Medical Center)
|
Dr. Tandan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Tandan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Apellis. Dr. Tandan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amylyx. The institution of Dr. Tandan has received research support from Alexion. The institution of Dr. Tandan has received research support from Apellis. The institution of Dr. Tandan has received research support from Cytokinetics. |
|
Vladimir Skljarevski, MD
(Eli Lilly and Company)
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
Jonathan Dissin, MD
(Albert Einstein Medical Center)
|
Dr. Dissin has received stock or an ownership interest from GlaxoSmithKline. Dr. Dissin has received stock or an ownership interest from Abbvie. |
|
Edward J. Bastyr III, MD
(Lilly Research Laboratories)
|
No disclosure on file |
|
Rainer W. Paine, MD, PhD
(Food and Drug Administration)
|
No disclosure on file |